Janssen receives new approval for Darzalex in Canada

Canadian authorities have approved the use of Darzalex, which is Genmab-developed, for treating the rare disease amyloidosis.

Photo: Tuala Hjarnø / Genmab / PR

Janssen is still working hard to promote its big seller Darzalex, and this is now paying off in Canada.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs